Databases - ALZFORUM
WEBThis interactive database captures two decades of research on fluid biomarkers for Alzheimer's disease. Curated measurements and related data from peer-reviewed articles are presented, as well as meta-analyses for selected biomarkers. This resource, developed in collaboration with Henrik Zetterberg and colleagues at the University of Gothenburg ...
ALZFORUM | NETWORKING FOR A CURE
WEB4 days ago · Everywhere, according to a new snRNA-Seq study of more than 400 postmortem brains. The authors identified one microglial subtype that promotes plaques, another that promotes tangles, and an astrocyte subtype that contributes to cognitive decline. Intriguingly, in brains with plaques but few …
Trontinemab - ALZFORUM
WEBMay 9, 2024 · Overview. Name: Trontinemab Synonyms: RO7126209, RG6102 , Brain shuttle gantenerumab Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 1/2) Company: Hoffmann-La Roche Background. RO7126209 is a new version of the anti-amyloid monoclonal antibody gantenerumab, engineered to more easily cross the blood ...
Donanemab | ALZFORUM
WEBFeb 14, 2019 · Overview. Name: Donanemab Synonyms: N3pG-Aβ Monoclonal Antibody, LY3002813, Kisunla Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Approved) Company: Eli Lilly & Co. Background. Donanemab, aka N3pG, is a humanized IgG1 monoclonal antibody developed from mouse mE8-IgG2a. This biologic drug …
Citalopram Calms Agitation in Alzheimer’s, but Carries Risks
WEBThey found that the antidepressant citalopram calms Alzheimer’s patients, which reduces stress for caregivers. However, at the tested dose of 30 mg daily, citalopram comes with safety risks of its own, including abnormal heart rhythms. The Food and Drug Administration now recommends that elderly patients take no more than 20 mg citalopram ...
Leqembi - ALZFORUM
WEBOverview. Name: Leqembi Synonyms: Lecanemab-irmb, BAN2401, mAb158 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Approved) Company: BioArctic AB, Biogen, Eisai Co., Ltd. Background. BAN2401 is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble ...
AL002 - ALZFORUM
WEBNov 6, 2023 · AL002a, a variant of AL002 that recognizes mouse TREM2, reportedly doubled the number of CD11b-positive microglia in cortex and hippocampus 72 hours after injection in APP/PS1 mice. Microglia expressed more pro-inflammatory and repair genes, and nearby amyloid deposits were nearly halved (Dec 2016 conference news).
What Is Early Onset Familial Alzheimer Disease (eFAD)?
WEBEarly onset FAD is acutely tragic because the patient faces a relentless and progressive loss of brain function so prematurely, while he or she is still physically vigorous. As a result, eFAD is often accompanied by psychiatric complications such as depression and agitation.
Bepranemab - ALZFORUM
WEBJan 23, 2022 · Overview. Name: Bepranemab Synonyms: UCB0107 , UCB 0107 , Antibody D Therapy Type: Immunotherapy (passive) Target Type: Tau Condition(s): Progressive Supranuclear Palsy, Alzheimer's Disease U.S. FDA Status: Progressive Supranuclear Palsy (Phase 1), Alzheimer's Disease (Phase 2) Company: Hoffmann-La Roche, UCB S.A. Background. This humanized, monoclonal IgG4 antibody binds to the central region ...
Memantine—Good for a Year, But Little Disease Modification
WEBJan 16, 2018 · 12 Jan 2006. The drug memantine is a safe and effective therapy that helps patients suffering from moderate to severe Alzheimer disease for up to a year. However, evidence that the drug might slow the underlying pathology is weak. These are the two main conclusions of a 24-week, open-label extension of a 28-week, randomized clinical trial.